Integration of GLP-1 Agonists With Other Weight Loss Management Drugs in a Rare Genetic Disorders of Obesity Clinic Setmelanotide, a melanocortin-4 receptor (MC4R) agonist, is the first FDA-approved drug for managing weight in rare genetic disorders of obesity, such as pro-opiomelanocortin (POMC) deficiency, leptin receptor deficiency, proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency, and Bardet-Biedl syndrome
Interestingly, mitochondrial dysfunction in PBMCs has also been recently related to another chronic manifestation of liver disease
[DOI] [PMC free article] [PubMed] [Google Scholar] 174.Hossain K.R., Li X., Zhang T., Paula S., Cornelius F., Clarke R.J
They searched across multiple databases, including Cochrane Library, Web of Science, PubMed, Google Scholar, and Science Direct, to identify studies on IBS and related medications
However, concerns have arisen regarding its impact on muscle mass
Furthermore, by lowering inflammation in the body, it can help reduce symptoms of some conditions